表紙
市場調查報告書
商品編碼
991971

乾燥症(修格蘭氏症候群) (SS):市場機會分析與未來預測 (到2029年)

Sjogren's Syndrome (SS) - Opportunity Analysis and Forecasts to 2029

出版日期: | 出版商: GlobalData | 英文 118 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球主要7個國家 (7MM:美國,法國,德國,義大利,西班牙,英國,日本) 的乾燥症(修格蘭氏症候群) (SS) 治療藥市場,預計今後10年有大幅度變化緩慢成長。

本報告提供全球乾燥症(修格蘭氏症候群) (SS) 醫藥品 (治療藥,緩解疾病藥等) 相關最新的研究、開發趨勢與,今後的市場趨勢預測分析,疾病概要和目前的治療方法,未滿足需求、市場機會的評估,患病人數、市場規模的預測值 (2019年∼2029年),臨床試驗的進展,新治療藥的開發平台評估,今後的市場、技術趨勢等調查。

目錄

第1章 目錄

第2章 乾燥症(修格蘭氏症候群) (SS):摘要整理

  • 乾燥症(修格蘭氏症候群):市場成長預測 (2019年∼2029年)
  • 乾燥症(修格蘭氏症候群)市場:研究開發策略
  • 乾燥症(修格蘭氏症候群)市場:高水準的未滿足需求
  • 新生技藥品的登場:乾燥症(修格蘭氏症候群)的治療範例的變革
  • 醫生方面的見解

第3章 簡介

第4章 疾病概要

  • 病因與病情生理
    • 病因
    • 病理學
    • 症狀
    • 預後
  • 分類/病期分類系統

第5章 流行病學

  • 疾病的背景
  • 危險因素與並存症
  • 全球過去趨勢
    • SS的已受診盛行率 (%)
  • 預測手法
    • 資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • SS的流行病學的預測 (2019年∼2029年)
    • SS的已受診患病人數
    • pSS的已受診患病人數
    • sSS的已受診患病人數
    • pSS的已受診患病人數:男女
    • pSS的已受診患病人數:各ESSDAI指標
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第6章 目前治療選擇

  • 概要

第7章 未滿足需求與市場機會的評估

  • 概況
  • 腺內、腺外症狀的治療的認證
  • 初期的乾燥症(修格蘭氏症候群)的診斷
  • 對乾燥症(修格蘭氏症候群)的一般市民和患者的意識提高
  • 更佳臨床試驗端點

第8章 研究開發 (R&D) 策略

  • 概要
    • 為了其他自體免疫疾病所販售生物學療法的評估
    • 臨床實驗的效率改善
  • 臨床實驗的設計
    • 端點的選擇
    • 蘊藏標準
    • 募集受實驗者

第9章 開發平台評估

  • 概要
  • 創新的初期階段的方法
  • 臨床實驗中的其他醫藥品

第10章 開發平台評估分析

  • 主要的開發平台藥物:臨床方面的比較分析
  • 主要的開發平台藥物:商業性的比較分析
  • 各企業的評估
  • 主要國家市場分析 (今後10年份)
    • 美國
    • 歐洲主要5個國家 (5EU)
    • 日本

第11章 附錄

目錄
Product Code: GDHC117POA

Sjogren's syndrome (SS) is a chronic and systemic autoimmune inflammatory disorder in which an initial immunological attack that primarily targets the lacrimal and salivary glands. Although most characteristically clinical features are ocular and oral dryness due to reduced secretory functions, systemic features including cutaneous, respiratory, renal, hepatic, neurological, and vascular involvement often occur. In addition, there is a higher incidence of lymphoma associated with SS patients.

The SS market is expected to undergo significant change and moderate growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan) covered in this report. In this report, GlobalData analyses the current symptomatic SS treatment landscape and provides detailed insights into the market dynamics of this systemic autoimmune disease. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for SS, and their sales projections within SS over the 2019-2029 forecast period.

The SS market is expected to undergo significant change and growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan) covered in this report. In this report, GlobalData analyzes the current SS symptomatic and systemic treatment landscape and provides detailed insights into the market dynamics of this autoimmune disease. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for SS, and their sales projections within SS over the 2019-2029 forecast period.

With no currently approved systemic treatments, the SS treatment algorithm varies among physicians and institutions, but is largely consists of off-label therapies, immunosuppressants, and corticosteroids. Over the forecast period GlobalData expects that treatment options for SS patients will significantly expand as pipeline products are approved and launched for the systemic treatment of SS. The launches of products with demonstrated efficacy will be a major driver of growth over the next 10 years.

Key Questions Answered

  • How will the symptomatic and systemic SS treatment landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2019-2029?
  • What SS treatments are in clinical development?
  • How do the clinical and commercial attributes of SS treatment candidates in development compare with one another, and against conventional treatment options?
  • What are the remaining unmet needs in SS diagnosis and treatment?
  • What drivers and barriers will affect SS sales in the 7MM over the forecast period?

Scope

  • Overview of therapies used in symptomatic, conventional and off-label systemic treatments in SS.
  • Top-line SS treatment market revenue from 2019-2029. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include currently available treatments and off-label products, unmet needs and opportunities, and the drivers and barriers affecting SS sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of pipeline products.
  • Analysis of the current and future market competition in the global SS market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global SS treatment market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SS market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Sjogren's Syndrome: Executive Summary

  • 2.1 Growth in the Sjogren's Syndrome Market Is Expected from 2019 to 2029
  • 2.2 R&D Strategies for the Sjogren's Syndrome Market
  • 2.3 High Level of Unmet Need Persists in the Sjogren's Syndrome Marketplace
  • 2.4 The Arrival of Novel Biologics Will Transform the Sjogren's Syndrome Treatment Paradigm
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
    • 4.1.3 Symptoms
    • 4.1.4 Prognosis
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
    • 5.3.1 Diagnosed Prevalence of SS (%)
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Sources Not Used
    • 5.4.3 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for SS (2019-2029)
    • 5.5.1 Diagnosed Prevalent Cases of pSS
    • 5.5.2 Diagnosed Prevalent Cases of sSS
    • 5.5.3 Age-Specific Diagnosed Prevalent Cases of pSS
    • 5.5.4 Sex-Specific Diagnosed Prevalent Cases of pSS
    • 5.5.5 Diagnosed Prevalent Cases of pSS by ESSDAI
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of Analysis
    • 5.6.3 Strengths of Analysis

6 Current Treatment Options

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Approval of Treatments for Glandular and Extraglandular Manifestations
  • 7.3 Earlier Sjogren's Syndrome Diagnosis
  • 7.4 Improved Public and Patient Awareness of Sjogren's Syndrome
  • 7.5 Better Clinical Trial Endpoints

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Evaluation of Biologic Therapies Marketed for Other Autoimmune Diseases
    • 8.1.2 Increasing Efficiency of Clinical Trials
  • 8.2 Clinical Trials Design
    • 8.2.1 Endpoint Selection
    • 8.2.2 Inclusion Criteria
    • 8.2.3 Patient Recruitment

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Innovative Early-Stage Approaches
  • 9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

  • 10.1 Clinical Benchmark of Key Pipeline Drugs
  • 10.2 Commercial Benchmark of Key Pipeline Drugs
  • 10.3 Competitive Assessment
  • 10.4 Top-Line 10-Year Forecast
    • 10.4.1 US
    • 10.4.2 5EU
    • 10.4.3 Japan

11 Appendix

List of Tables

List of Tables

  • Table 1: Sjogren's Syndrome: Key Metrics in the 7MM
  • Table 2: Classification Criteria for Sjogren's Syndrome
  • Table 3: The EULAR Sjogren's syndrome disease activity index (ESSDAI)
  • Table 4: Risk Factors and Comorbidities for SS
  • Table 5: Key Marketed and Off-Label Products for Sjogren's Syndrome, 7MM
  • Table 6: Innovative Early-Stage Approaches for Sjogren's Syndrome, 2021
  • Table 7: Drugs in Development for Sjogren's Syndrome, 2021
  • Table 8: Clinical Benchmark of Key Pipeline Drugs - SS
  • Table 9: Commercial Benchmark of Key Pipeline Drugs - SS
  • Table 10: Key Events Impacting Sales for Primary Sjogren's Syndrome, 2019-2029
  • Table 11: Primary Sjogren's Syndrome Market - Global Drivers and Barriers, 2019-2029
  • Table 12: Key Historical and Projected Launch Dates for Sjogren's Syndrome
  • Table 13: Key Historical and Projected Patent Expiry Dates for Sjogren's Syndrome
  • Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Sjogren's Syndrome in 2019 and 2029
  • Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs for Sjogren's Syndrome Benchmarked Against Off-Label Orencia
  • Figure 3: Pathophysiology of Sjogren's Syndrome
  • Figure 4: 7MM, Diagnosed Prevalence of SS (%), Men and Women, ≥18 Years, 2019
  • Figure 5: 7MM, Sources Used and Not Used for the Diagnosed Prevalence of pSS
  • Figure 6: 7MM, Sources Used for the Diagnosed Prevalence of sSS
  • Figure 7: 7MM, Sources Used for the Diagnosed Prevalence of pSS by ESSDAI
  • Figure 8: 7MM, Diagnosed Prevalent Cases of pSS, Men and Women, Ages ≥18 Years, 2019
  • Figure 9: 7MM, Diagnosed Prevalent Cases of sSS, Men and Women, Ages ≥18 Years, 2019
  • Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Men and Women, Ages ≥18 Years, 2019
  • Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of pSS, Men and Women, Ages ≥18 Years, 2019
  • Figure 12: 7MM, Diagnosed Prevalent Cases of pSS by ESSDAI, Men and Women, Ages ≥18 Years, 2019
  • Figure 13: Unmet Needs and Opportunities in Sjogren's Syndrome
  • Figure 14: Overview of the Development Pipeline in Sjogren's Syndrome
  • Figure 15: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Sjogren's Syndrome in the 7MM During the Forecast Period
  • Figure 16: Competitive Assessment of Pipeline Drugs Benchmarked Against Off-Label Therapy, Orencia
  • Figure 17: Global (7MM) Sales Forecast by Country for Primary Sjogren's Syndrome in 2019 and 2029
  • Figure 18: Global Sales Forecast by Class for Primary Sjogren's Syndrome in 2019 and 2029
  • Figure 19: Sales Forecast by Class for Primary Sjogren's Syndrome in the US in 2019 and 2029
  • Figure 20: Sales Forecast by Class for Primary Sjogren's Syndrome in the 5EU in 2019 and 2029
  • Figure 21: Sales Forecast by Class for Primary Sjogren's Syndrome in Japan in 2019 and 2029